Actively Recruiting
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
Led by Matthew Bucknor · Updated on 2025-08-13
20
Participants Needed
1
Research Sites
335 weeks
Total Duration
On this page
Sponsors
M
Matthew Bucknor
Lead Sponsor
F
Focused Ultrasound Foundation
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study is a single site, single-arm, feasibility study to evaluate the safety and efficacy of MRgFUS using the ExAblate 2100 System for the partial ablation of undifferentiated pleomorphic sarcomas.
CONDITIONS
Official Title
Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Men and women 18 years or older
- ECOG performance status score of 0 or 1
- Biopsy-proven new diagnosis of undifferentiated pleomorphic sarcoma within the last 6 months or lesion suspected as metastatic UPS on recent CT or MRI
- Target tumor size between 2 cm and 20 cm in maximum diameter
- Tumor located in soft tissues of chest, abdomen, pelvis, or extremities accessible by the ExAblate device
- Tumor must be more than 1 cm away from critical structures such as skin, major nerves, vessels, nerve roots, solid organs, and bowel
- Tumor clearly visible on non-contrast MRI
- For newly diagnosed UPS, tumor must be surgically resectable as documented by tumor board or surgeon
- Patients receiving standard neoadjuvant chemotherapy may be included if all other criteria are met
You will not qualify if you...
- Need for systemic corticosteroids or immunosuppressive drugs within 14 days before MRgFUS treatment
- History of interstitial lung disease or other active cancers that may affect immune results
- Previous malignancies except non-melanoma skin cancers
- Unresolved toxicities from prior cancer therapy except hair loss and fatigue
- Recovery from major surgery or trauma less than 14 days before study procedure
- Acute medical conditions, unstable heart status, or severe cerebrovascular disease
- Treatment with any investigational drug within 28 days before treatment
- Contraindications to MRI including metal implants causing safety issues, claustrophobia, weight over 400 pounds (181.4 kg), pregnancy, or allergy to MRI contrast
- Unable to safely receive anesthesia or sedation or allergy to sedation medications
- Inability to communicate verbally with study staff
- For newly diagnosed patients only: prior or planned neoadjuvant radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of California, San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
Research Team
L
Louise Magat
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here